People

The Team

Eliezer Van Allen, MD - Principal Investigator

Dr. Van Allen is an Associate Professor of Medicine at Harvard Medical School, a clinician at Dana-Farber/Partners Cancer Care, and an Associate Member at the Broad Institute of MIT and Harvard. His research focuses on computational cancer genomics, the application of new molecular profiling technologies to advance precision cancer medicine, and studying resistance to cancer therapeutics. As both a computational biologist and medical oncologist, he has specific expertise in clinical computational oncology and the development of algorithms to analyze and interpret genomic data for clinically focused questions. Overall, his research will make important contributions to the field of precision cancer medicine and resistance to targeted therapeutics via expertise and study in translational and clinical bioinformatics.

Originally from Los Angeles, CA, he studied Symbolic Systems at Stanford University, obtained his M.D. from UCLA, and completed a residency in internal medicine at UCSF before coming to Boston and completing a medical oncology fellowship at the Dana-Farber/Partners Cancer Care program.

Lauren Miller-Jones, BA
Lab Administrator

Saud AlDubayan, MD
Instructor, Harvard Medical School
Saud is a board-certified clinical geneticist and computational biologist in the Center for Cancer Genetics and Prevention at DFCI. Saud obtained his Medical Doctorate degree in 2009 and has done clinical training in adult medicine at the University of Toronto as well as clinical genetics and genomics at Harvard Medical School. Saud also did postdoctoral research training in computational biology at DFCI/Broad as well as translational genomics at Harvard Clinical and Translational Academy. In addition to clinically evaluating patients with inherited cancer-predisposition syndromes, Saud is also a dedicated scientist whose research interest has focused on exploring the utility of integrative DNA-repair centered analyses of paired germline and tumor genetic and transcriptomic data for informing clinical decision making. Saud’s current research work aims to explore novel inherited and somatic genomic predictors of cancer risk, cancer progression and chemoresistance in large cohorts of cancer patients.

Alice Bosma-Moody, BS
HST MD Program

Kevin Bi, BS
Associate Computuational Biologist (single cell analysis)

Sabrina Camp, BS
Associate Computational Biologist (germline-somatic interactions)

Jake Conway, BS (Bioinformatics)
Graduate Student, Bioinformatics and Integrative Genomics

Alexis Coolidge, BA (HMS MD Pathways)

Jett Crowdis, BS
Associate Computational Biologist

Felix Dietlein, MD, PhD
Instructor, Harvard Medical School

Ziad ElBakouny, MD
Research Fellow

Haitham Elmarakeby, PhD (Computer Science)
Instructor, Harvard Medical School

Riaz Gillani, MD
Pediatric Hematology/Oncology Fellow (Boston Children's Hospital)

Seunghun Han, BS
Graduate Student, BBS

Meng Xiao He, AB (Molecular and Cellular Biology)
Graduate Student, Biophysics
Meng Xiao is a student in the Harvard Biophysics PhD program. In the Van Allen lab, he mainly focuses on single-cell RNA-sequencing but is broadly interested in genetics. Having worked as a software engineer before returning to Harvard, he is interested in practical uses for his training in biology and computer science.

Alma Imamovic, MS
Associate Computational Biologist

Sophia Kamran, MD
Instructor, Radiation Oncology (MGH)

Tanya Keenan, MD MPH
Medical Oncology Fellow, Dana-Farber Cancer Institute
Tanya is a medical oncology fellow, who joined the Van Allen lab after completing an MPH in epidemiology at Hopkins and internal medicine residency and chief residency at MGH. She is driven to improve responses to immunotherapy in breast cancer by investigating mechanisms of resistance to checkpoint blockade.

Aditi Limaye, Undergraduate Research Student

Derek Liu, BS (HST MD program)

Jackson Nyman, BS
Graduate Student, Systems Biology

Jihye Park, PhD
Lead Scientist, Dana-Farber Cancer Institute

Brendan Reardon, BS (Physics)
Associate Computational Biologist
Brendan originally conducted research in astrophysics while studying physics at Brandeis University before migrating to computational biology and clinical computational oncology. His research is now motivated by the goal of improving clinical interpretation in cancer genomics, especially through integrative approaches.